ZVRA Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Zevra Therapeutics, Inc. had $106M of revenue in fiscal 2025, up 350.9% on the year before. Over five years, revenue changed +51.6% a year on average.
Last close Β· Oct 23, 2026
$9.81
5.0%Hi! I read Zevra Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+350.9%
Yes. Sales grew 350.9% last year.
Does it make a profit?
78.2%
Yes. It keeps 78.2% of every sale as profit.
Does profit turn into cash?
β2.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
10.4x
One share costs 10.4 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Zevra Therapeutics, Inc. had $106M of revenue in fiscal 2025, up 350.9% on the year before. Over five years, revenue changed +51.6% a year on average. Its operating margin was β59.1%, up 309.4Β pts: of every 100 in sales, about β59 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Zevra Therapeutics, Inc. made $83.2M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$2.4M in fiscal 2025, β2.3% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $2.5M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$2.5M
6 insiders
Of sales under plans
95%
$2.4M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 12, 2026 | Neil F. McFarlanePresident and CEO, Director | Sold plan | 20,000 | $11.25 | $0.2M | Form 4 |
| Aug 14, 2026 | Rahsaan ThompsonChief Legal & Compliance | Sold plan | 42,666 | $11.13 | $0.5M | Form 4 |
| Aug 10, 2026 | Corey Michael WattonDirector | Sold | 12,300 | $11.25 | $0.1M | Form 4 |
| Jun 22, 2026 | Rahsaan ThompsonChief Legal & Compliance | Sold plan | 34,557 | $12.68 | $0.4M | Form 4 |
| May 11, 2026 | Rahsaan ThompsonChief Legal & Compliance | Sold plan | 1,794 | $11.30 | $0.0M | Form 4 |
| Feb 9, 2026 | Neil F. McFarlanePresident and CEO, Director | Sold plan | 14,625 | $8.56 | $0.1M | Form 4 |
| Feb 3, 2026 | Joshua SchaferCco | Sold plan | 10,500 | $9.19 | $0.1M | Form 4 |
| Feb 3, 2026 | Timothy J. SangiovanniSVP, Finance & Corp Controller | Sold plan | 3,000 | $9.18 | $0.0M | Form 4 |
| Feb 2, 2026 | Neil F. McFarlanePresident and CEO, Director | Sold plan | 91,000 | $9.38 | $0.9M | Form 4 |
| Jan 30, 2026 | Adrian W QuartelChief Medical Officer | Sold plan | 4,533 | $8.83 | $0.0M | Form 4 |
| Jan 30, 2026 | Joshua SchaferCco | Sold plan | 3,375 | $8.83 | $0.0M | Form 4 |
| Jan 30, 2026 | Rahsaan ThompsonChief Legal & Compliance, Secretary | Sold plan | 4,080 | $8.83 | $0.0M | Form 4 |
| Jan 30, 2026 | Timothy J. SangiovanniSVP, Finance & Corp Controller | Sold plan | 1,750 | $8.82 | $0.0M | Form 4 |
| Oct 10, 2025 | Neil F. McFarlanePresident and CEO, Director | Sold plan | 19,500 | $10.82 | $0.2M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Zevra Therapeutics, Inc. has $129M more cash than debt.
Cash, debt and the ratios that show how comfortably Zevra Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $112M | $82.4M | $67.7M | $69.5M | $191M |
| Debt incl. finance leases | β | β | $5.1M | $59.5M | $61.9M |
| Debt / equity | β | β | 0.1x | 1.5x | 0.4x |
| Interest coverage | 34.2x | β127.1x | β33.0x | β11.8x | β7.9x |
| Current ratio | 27.2x | 7.7x | 1.2x | 2.5x | 5.7x |
| Quick ratio | 27.2x | 7.7x | 1.2x | 2.5x | 5.6x |
| Total assets | $133M | $115M | $172M | $178M | $285M |
| Total liabilities | $5.8M | $40.2M | $110M | $138M | $130M |
| Shareholders' equity | $102M | $75.1M | $61.9M | $39.7M | $155M |
| Net debt (β = net cash) | β | β | β$62.7M | β$10.0M | β$129M |
KIRA Β· Its return on capital was β236.3%: every 100 invested in the business earned about β236 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Zevra Therapeutics, Inc. passes 5 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | 1 / 7 | 3 / 8 | 3 / 8 | 4 / 7 | 2 / 7 | 2 / 7 | 2 / 7 | 5 / 8 |
| Accruals ratio | 15.6% | β15.0% | β5.7% | β4.2% | β99.7% | β26.4% | β6.5% | β8.7% | β20.5% | 36.7% |
| Altman Z'' | β2.58 | β10.76 | β38.88 | β89.20 | β78.94 | 17.64 | β5.92 | β8.41 | β10.32 | β0.84 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | β | $0.0M | $12.8M | $13.3M | $28.7M | $10.2M | $27.5M | $23.6M | $106M |
| Gross profit | β | β | $0.0M | $2.8M | β | $26.6M | $9.9M | $24.5M | β | β |
| Research and development | $20.5M | $20.6M | $41.8M | $19.4M | $8.8M | $10.2M | $19.8M | $39.8M | $42.1M | $12.7M |
| Operating income | β$37.5M | β$33.4M | β$55.9M | β$20.3M | β$5.6M | $7.7M | β$42.6M | β$49.6M | β$87.0M | β$62.9M |
| Interest expense | $5.5M | $5.8M | $5.5M | $4.9M | $4.8M | $0.2M | $0.3M | $1.5M | $7.4M | $8.0M |
| Pretax income | β$16.5M | β$43.4M | β$56.6M | β$24.5M | β$12.8M | β$8.5M | β$26.8M | β$46.0M | β$90.1M | $86.7M |
| Income tax | β$0.0M | β$0.0M | β$0.1M | β$0.0M | β$0.0M | $0.0M | β$0.0M | $0.0M | $15.4M | $3.4M |
| Net income | β$16.5M | β$43.4M | β$56.5M | β$24.5M | β$12.8M | β$8.6M | β$26.8M | β$46.0M | β$106M | $83.2M |
| Net income to common | β | β | β | β | β$12.8M | β$62.9M | β$26.8M | β$46.0M | β$106M | $77.6M |
| Diluted EPS | β$1.13 | β$2.96 | β$3.15 | β$13.23 | β$3.21 | β$2.11 | β | β | β$2.28 | $1.35 |
| Diluted shares | 0.01B | 0.01B | 0.02B | 0.00B | 0.00B | 0.03B | β | β | 0.05B | 0.06B |
| Cash flow | ||||||||||
| Cash from operations | β$29.8M | β$33.1M | β$54.2M | β$23.7M | β$1.9M | $10.4M | β$18.7M | β$33.5M | β$69.7M | β$1.6M |
| Capital expenditure | $0.6M | $0.2M | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.3M | $0.0M | $0.8M |
| Free cash flow | β$30.4M | β$33.3M | β$54.2M | β$23.8M | β$2.0M | $10.3M | β$18.8M | β$33.8M | β$69.7M | β$2.4M |
| Depreciation and amortization | $0.2M | $0.3M | $0.3M | $0.3M | $0.3M | $0.3M | $0.9M | $1.0M | $6.4M | $4.1M |
| Stock-based compensation | $6.6M | $4.6M | $6.5M | $4.4M | $2.5M | $2.4M | $4.3M | $6.0M | $14.9M | $12.6M |
| Acquisitions | β | β | β | β | β | $0.0M | $14.1M | $30.4M | $0.0M | β |
| Share buybacks | β | β | β | β | $0.0M | $2.8M | $4.7M | $3.4M | $0.0M | β |
| Dividends and buybacks | β | β | β | β | $0.0M | $2.8M | $4.7M | $3.4M | $0.0M | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $67.8M | $42.2M | $21.7M | $3.2M | $4.2M | $112M | $82.4M | $67.7M | $69.5M | $191M |
| Total debt | β | $92.7M | $81.4M | $77.3M | $67.7M | β | β | $5.1M | $59.5M | $61.9M |
| Finance lease liabilities | β | β | β | $0.4M | $0.2M | $0.0M | $0.0M | $0.0M | β | β |
| Current assets | $74.4M | $45.9M | $23.7M | $7.0M | $8.4M | $115M | $92.8M | $86.9M | $86.0M | $223M |
| Current liabilities | $6.6M | $11.5M | $12.0M | $5.4M | $7.5M | $4.2M | $12.0M | $73.7M | $34.1M | $39.3M |
| Inventory | β | β | β | β | β | β | $0.7M | $0.0M | $2.0M | $1.7M |
| Property and equipment, net | $2.0M | $2.0M | $1.8M | $1.5M | $1.0M | $0.9M | $0.8M | $0.7M | $0.4M | $0.5M |
| Goodwill | β | β | β | β | β | β | $0.0M | $4.7M | $4.7M | $4.7M |
| Intangible assets | β | β | β | β | β | β | $0.0M | $69.2M | $69.0M | $6.4M |
| Total assets | $84.9M | $52.5M | $26.7M | $10.5M | $11.2M | $133M | $115M | $172M | $178M | $285M |
| Total liabilities | $104M | $110M | $93.3M | $85.0M | $77.6M | $5.8M | $40.2M | $110M | $138M | $130M |
| Preferred stock | $0.0M | $0.0M | β | β | β | $0.0M | $0.0M | β | $0.0M | $0.0M |
| Shareholders' equity | β$18.7M | β$57.5M | β$66.6M | β$74.5M | β$66.4M | $102M | $75.1M | $61.9M | $39.7M | $155M |
| Margins | ||||||||||
| Gross margin | β | β | β | 22.1% | β | 92.8% | 97.8% | 89.3% | β | β |
| Operating margin | β | β | β | β158.4% | β42.2% | 27.0% | β418.9% | β180.6% | β368.5% | β59.1% |
| EBITDA margin | β | β | β | β156.0% | β40.2% | 27.9% | β409.6% | β177.0% | β341.4% | β55.3% |
| Net margin | β | β | β | β191.0% | β96.0% | β29.9% | β263.5% | β167.7% | β446.9% | 78.2% |
| FCF margin | β | β | β | β185.1% | β14.8% | 36.1% | β185.1% | β123.2% | β295.0% | β2.3% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β | β | β | β231.6% | β236.3% |
| Return on capital employed | β47.9% | β81.5% | β379.2% | β400.7% | β152.7% | 6.0% | β41.2% | β50.3% | β60.4% | β25.6% |
| Return on equity | β | β | β | β | β | β48.5% | β30.3% | β67.2% | β207.8% | 85.7% |
| Return on assets | β19.5% | β63.2% | β142.6% | β131.7% | β117.5% | β11.9% | β21.6% | β32.0% | β60.2% | 36.0% |
| Return on tangible equity | β | β | β | β | β | β61.9% | β35.6% | β | β | 54.1% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | 3.5% | 115.6% | β64.5% | 170.3% | β14.0% | 350.9% |
| FCF growth | β | β | β | β | β | β | β282.0% | β | β | β |
| Share count change | β | 0.4% | 22.4% | β89.7% | 114.8% | 647.7% | β | β | β | 23.8% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | β | β | β | 0.1x | 1.5x | 0.4x |
| Interest coverage | β6.8x | β5.8x | β10.2x | β4.2x | β1.2x | 34.2x | β127.1x | β33.0x | β11.8x | β7.9x |
| Current ratio | 11.2x | 4.0x | 2.0x | 1.3x | 1.1x | 27.2x | 7.7x | 1.2x | 2.5x | 5.7x |
| Quick ratio | 11.2x | 4.0x | 2.0x | 1.3x | 1.1x | 27.2x | 7.7x | 1.2x | 2.5x | 5.6x |
| Capital allocation | ||||||||||
| Capex / revenue | β | β | β | 0.2% | 0.2% | 0.4% | 0.9% | 1.1% | 0.0% | 0.8% |
| Stock comp / revenue | β | β | β | 34.3% | 18.7% | 8.5% | 42.3% | 21.7% | 63.1% | 11.9% |
| Payouts / FCF | β | β | β | β | β | 27.2% | β | β | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 1.0 | 3.0 | 3.0 | 4.0 | 2.0 | 2.0 | 2.0 | 5.0 |
| Altman Z'' | β2.6 | β10.8 | β38.9 | β89.2 | β78.9 | 17.6 | β5.9 | β8.4 | β10.3 | β0.8 |
| Accruals ratio | 15.6% | β15.0% | β5.7% | β4.2% | β99.7% | β26.4% | β6.5% | β8.7% | β20.5% | 36.7% |
Source: SEC EDGAR XBRL filings (CIK 0001434647). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
